TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer.

Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, Translational Breast Cancer Research Consortium
Clin Cancer Res. 2020 26 (9): 2111-2123

PMID: 31822498 · PMCID: PMC7196503 · DOI:10.1158/1078-0432.CCR-19-2170

MeSH Terms (16)

Androgen Receptor Antagonists Antineoplastic Combined Chemotherapy Protocols Benzamides Class I Phosphatidylinositol 3-Kinases Female Humans Imidazoles Middle Aged Neoplasm Metastasis Nitriles Oxazepines Phenylthiohydantoin Protein Kinase Inhibitors Receptors, Androgen Survival Rate Triple Negative Breast Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: